Good morning :)
Place Order
Add to Watchlist

J B Chemicals and Pharmaceuticals Ltd

JBCHEPHARM Share Price

1,812.700.94% (+16.80)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

JBCHEPHARM Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

JBCHEPHARM Performance & Key Metrics

JBCHEPHARM Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
42.499.590.86%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.496.520.85%

JBCHEPHARM Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
92%
Analysts have suggested that investors can buy this stock

from 13 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

JBCHEPHARM Company Profile

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs).

Investor Presentation

View older View older 

May 14, 2025

PDF
View Older Presentations

JBCHEPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 

JBCHEPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.50
36.50
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
PE Ratio
19.39
19.39
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
PE Ratio
56.06
56.06
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
PE Ratio
21.17
21.17
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
Compare with Peers

JBCHEPHARM Sentiment Analysis

JBCHEPHARM Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

JBCHEPHARM Stock Summary · May 2025

In Q4 FY25, the company demonstrated robust operational momentum with a 10% revenue increase and a 15% rise in net profit, driven by strong domestic performance, particularly in the chronic portfolio, which outpaced industry growth. While the domestic market remains a cornerstone, contributing 60% of revenues, international expansion, especially in the CDMO segment, is poised for significant growth through new product launches and strategic partnerships. Despite facing competitive pressures in the branded generics space, the company is committed to enhancing profitability through improved margins and operational efficiencies. Ongoing investments and a diversified revenue stream position the company favorably for future growth, even as it navigates market challenges and evolving dynamics.

JBCHEPHARM Stock Growth Drivers
JBCHEPHARM Stock Growth Drivers
8
  • Strong Financial Performance

    The company reported a 10% increase in revenue to INR 949 crore for Q4 FY25,

  • Robust Prescription Growth

    The company has achieved a prescription growth rate of 17% CAGR over the past four

JBCHEPHARM Stock Challenges
JBCHEPHARM Stock Challenges
4
  • Decline in API Business

    The API business has been experiencing a decline over the past two years, primarily due

  • Subdued Growth in Indian Pharmaceutical Market

    The Indian pharmaceutical market has experienced subdued growth, currently at around 8%, with volume growth

JBCHEPHARM Forecast

JBCHEPHARM Forecasts

Price

Revenue

Earnings

JBCHEPHARM

JBCHEPHARM

Income

Balance Sheet

Cash Flow

JBCHEPHARM Income Statement

JBCHEPHARM Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.89%, vs industry avg of 9.02%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.77% to 0.92%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 23.36%, vs industry avg of 15.29%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue1,394.451,445.491,684.641,825.402,154.902,463.473,159.223,521.453,956.313,956.31
Raw Materialssubtract519.54544.41615.76634.79742.76860.381,179.201,228.902,886.152,886.15
Power & Fuel Costsubtract54.8958.2863.2961.5462.6071.4791.5488.08
Employee Costsubtract217.34251.10288.18322.92340.60439.24543.45601.41
Selling & Administrative Expensessubtract174.28205.31234.51228.72233.56358.90448.81501.94
Operating & Other expensessubtract145.85131.98135.62159.19102.59150.79190.53166.96
Depreciation/Amortizationsubtract47.2256.9755.6466.3268.6772.66114.41138.32171.04171.04
Interest & Other Itemssubtract5.373.494.653.037.245.1236.0544.3311.7311.73
Taxes & Other Itemssubtract45.8855.6193.5276.85148.92119.54145.40198.88227.81227.81
EPS10.858.2211.8117.2728.9824.9326.5035.6642.4542.50
DPS0.501.002.505.508.258.258.8812.2515.5015.25
Payout ratio0.050.120.210.320.280.330.330.340.370.36

JBCHEPHARM Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 14PDF
Feb 4PDF
Nov 7PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 9PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 24PDF
Feb 8PDF
Jan 10PDF
+2 more
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 27PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

JBCHEPHARM Stock Peers

JBCHEPHARM Past Performance & Peer Comparison

JBCHEPHARM Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
J B Chemicals and Pharmaceuticals Ltd42.499.590.86%
Sun Pharmaceutical Industries Ltd36.505.940.96%
Cipla Ltd22.974.521.07%
Dr Reddy's Laboratories Ltd19.393.880.61%

JBCHEPHARM Stock Price Comparison

Compare JBCHEPHARM with any stock or ETF
Compare JBCHEPHARM with any stock or ETF
JBCHEPHARM
Loading...

JBCHEPHARM Holdings

JBCHEPHARM Shareholdings

JBCHEPHARM Promoter Holdings Trend

JBCHEPHARM Promoter Holdings Trend

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 5.90%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

JBCHEPHARM Institutional Holdings Trend

JBCHEPHARM Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 3.66%

Tickertape Separator

JBCHEPHARM Shareholding Pattern

JBCHEPHARM Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding47.84%16.26%2.45%18.30%15.14%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

JBCHEPHARM Shareholding History

JBCHEPHARM Shareholding History

Dec '23MarJunSepDec '24Mar10.35%11.06%12.17%13.63%14.64%18.30%

Mutual Funds Invested in JBCHEPHARM

Mutual Funds Invested in JBCHEPHARM

No mutual funds holding trends are available

Top 5 Mutual Funds holding J B Chemicals and Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.5072%1.26%-0.20%56/69 (-7)
1.5071%1.61%-0.28%103/139 (-12)
0.9043%1.79%-0.32%11/103 (-3)

Compare 3-month MF holding change on Screener

JBCHEPHARM Insider Trades & Bulk Stock Deals

JBCHEPHARM Insider Trades & Bulk Stock Deals

Loading...

smallcases containing JBCHEPHARM stock

smallcases containing JBCHEPHARM stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have J B Chemicals and Pharmaceuticals Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

JBCHEPHARM's Wtg.
11.89%
11.89%
CAGR
20.66%
Growth & Income Model

Growth & Income Model

Created by Windmill Capital

JBCHEPHARM's Wtg.
6.86%
6.86%
CAGR
35.33%

JBCHEPHARM Events

JBCHEPHARM Events

JBCHEPHARM Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

JBCHEPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.58 every year

Dividends

Corp. Actions

Announcements

Legal Orders

JBCHEPHARM Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

JBCHEPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.58 every year

JBCHEPHARM Upcoming Dividends

JBCHEPHARM Upcoming Dividends

No upcoming dividends are available

JBCHEPHARM Past Dividends

JBCHEPHARM Past Dividends

Cash Dividend

Ex DateEx DateFeb 7, 2025

Interim
Interim | Div/Share: ₹8.50

Dividend/Share

8.50

Ex DateEx Date

Feb 7, 2025

Cash Dividend

Ex DateEx DateAug 14, 2024

Final
Final | Div/Share: ₹6.75

Dividend/Share

6.75

Ex DateEx Date

Aug 14, 2024

Cash Dividend

Ex DateEx DateFeb 16, 2024

Interim
Interim | Div/Share: ₹5.50

Dividend/Share

5.50

Ex DateEx Date

Feb 16, 2024

Cash Dividend

Ex DateEx DateAug 17, 2023

Final
Final | Div/Share: ₹9.25

Dividend/Share

9.25

Ex DateEx Date

Aug 17, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Interim
Interim | Div/Share: ₹8.50

Dividend/Share

8.50

Ex DateEx Date

Feb 17, 2023

JBCHEPHARM Stock News & Opinions

JBCHEPHARM Stock News & Opinions

Corporate
J B Chemicals & Pharmaceuticals allots 85,390 equity shares under ESOS

J B Chemicals & Pharmaceuticals has allotted 85,390 equity shares under ESOS. Consequently, the issued, subscribed and paid up capital has increased from 15,59,73,534 equity shares of Re. 1 each to 15,60,58,924 equity shares of Re. 1 each.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
J B Chemicals & Pharmaceuticals allots 1.12 lakh equity shares under ESOS

J B Chemicals & Pharmaceuticals has allotted 112,990 fully paid up equity shares of Re. 1/- each of the Company, to certain employees on exercise of stock options granted to them pursuant to JBCPL Employee Stock Option Scheme, 2021. An amount of Rs. 5,16,30,125 has been realised on exercise of 112,990 stock options. Consequently, the issued, subscribed and paid up capital has increased from 15,58,60,544 equity shares of Re. 1 each to 15,59,73,534 equity shares of Re. 1 each.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Board of J B Chemicals & Pharmaceuticals recommends final dividend

J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 700%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
J B Chemicals & Pharmaceuticals consolidated net profit rises 15.48% in the March 2025 quarter

Net profit of J B Chemicals & Pharmaceuticals rose 15.48% to Rs 145.69 crore in the quarter ended March 2025 as against Rs 126.16 crore during the previous quarter ended March 2024. Sales rose 10.18% to Rs 949.48 crore in the quarter ended March 2025 as against Rs 861.73 crore during the previous quarter ended March 2024. For the full year,net profit rose 19.35% to Rs 659.58 crore in the year ended March 2025 as against Rs 552.63 crore during the previous year ended March 2024. Sales rose 12.45% to Rs 3917.99 crore in the year ended March 2025 as against Rs 3484.18 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales949.48861.73 10 3917.993484.18 12 OPM %23.8522.99 -26.3425.74 - PBDT239.47205.34 17 1058.43889.83 19 PBT193.03164.60 17 887.39751.51 18 NP145.69126.16 15 659.58552.63 19 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
J B Chemicals & Pharmaceuticals allots 65,686 equity shares under ESOS

J B Chemicals & Pharmaceuticals has allotted 65,686 equity shares under ESOS on 05 May 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,56,77,208 equity shares of Re. 1 each to 15,57,42,894 equity shares of Re. 1 each.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
J B Chemicals & Pharmaceuticals schedules board meeting

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
JB Chemicals & Pharma receives USFDA approval for Bisoprolol Tablets

The approved product is the generic version of Zebeta (marketed by Teva Pharmaceuticals) and is indicated for the management of hypertension. JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates. The company's consolidated net profit jumped 21.7% to Rs 162.49 crore on a 14.1% rise in net sales to Rs 963.49 crore in Q3 FY25 over Q3 FY24. Shares of JB Chemicals & Pharmaceuticals rose 0.47% to Rs 1,652.95 on the BSE.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
J B Chemicals & Pharmaceuticals receives USFDA approval for Bisoprolol Tablets

J B Chemicals & Pharmaceuticals has received approval from United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Bisoprolol Tablets USP, 5 mg, and 10 mg, the generic version of Zebeta (Teva), which is indicated in the management of hypertension.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Volumes jump at J B Chemicals & Pharmaceuticals Ltd counter

Capri Global Capital Ltd, RHI Magnesita India Ltd, Gujarat Pipavav Port Ltd, MMTC Ltd are among the other stocks to see a surge in volumes on NSE today, 27 March 2025.J B Chemicals & Pharmaceuticals Ltd witnessed volume of 110.79 lakh shares by 14:14 IST on NSE, a 96.3 times surge over two-week average daily volume of 1.15 lakh shares. The stock dropped 5.32% to Rs.1,617.85. Volumes stood at 75510 shares in the last session.Capri Global Capital Ltd witnessed volume of 1106.42 lakh shares by 14:14 IST on NSE, a 18.26 times surge over two-week average daily volume of 60.60 lakh shares. The stock dropped 13.43% to Rs.168.70. Volumes stood at 467.18 lakh shares in the last session.RHI Magnesita India Ltd witnessed volume of 154.53 lakh shares by 14:14 IST on NSE, a 12.41 times surge over two-week average daily volume of 12.46 lakh shares. The stock increased 10.18% to Rs.512.50. Volumes stood at 1.74 lakh shares in the last session.Gujarat Pipavav Port Ltd recorded volume of 129.28 lakh shares by 14:14 IST on NSE, a 7.05 times surge over two-week average daily volume of 18.32 lakh shares. The stock gained 5.79% to Rs.142.26. Volumes stood at 11.18 lakh shares in the last session.MMTC Ltd witnessed volume of 111.59 lakh shares by 14:14 IST on NSE, a 5.42 times surge over two-week average daily volume of 20.60 lakh shares. The stock increased 6.40% to Rs.55.85. Volumes stood at 29.33 lakh shares in the last session.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
J B Chemicals & Pharmaceuticals allots 1,700 equity shares under ESOS

J B Chemicals & Pharmaceuticals has allotted 1,700 equity shares under ESOS on 18 March 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,56,75,508 equity shares of Re. 1 each to 15,56,77,208 equity shares of Re. 1 each.Powered by Capital Market - Live

3 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) today?

    The share price of JBCHEPHARM as on 24th June 2025 is ₹1812.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?

    The past returns of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share are
    • Past 1 week: 1.41%
    • Past 1 month: 4.88%
    • Past 3 months: 8.82%
    • Past 6 months: -3.43%
    • Past 1 year: 2.40%
    • Past 3 years: 135.45%
    • Past 5 years: 396.55%

  3. What are the peers or stocks similar to J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM)?
  4. What is the dividend yield % of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?

    The current dividend yield of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is 0.86.

  5. What is the market cap of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is ₹28026.62 Cr as of 24th June 2025.

  6. What is the 52 week high and low of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?

    The 52-week high of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is ₹2030 and the 52-week low is ₹1385.75.

  7. What is the PE and PB ratio of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) stock?

    The P/E (price-to-earnings) ratio of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is 42.49. The P/B (price-to-book) ratio is 9.59.

  8. Which sector does J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) belong to?

    J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) shares?

    You can directly buy J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.